



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

A subset of group A-like var genes encodes the malaria parasite ligands for binding to human brain endothelial cells

Citation for published version:

Claessens, A, Adams, Y, Ghumra, A, Lindergard, G, Buchan, CC, Andisi, C, Bull, PC, Mok, S, Gupta, AP, Wang, CW, Turner, L, Arman, M, Raza, A, Bozdech, Z & Rowe, JA 2012, 'A subset of group A-like var genes encodes the malaria parasite ligands for binding to human brain endothelial cells', *Proceedings of the National Academy of Sciences (PNAS)*, vol. 109, no. 26, pp. E1772–E1781.
<https://doi.org/10.1073/pnas.1120461109>

Digital Object Identifier (DOI):

[10.1073/pnas.1120461109](https://doi.org/10.1073/pnas.1120461109)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Publisher's PDF, also known as Version of record

Published In:

Proceedings of the National Academy of Sciences (PNAS)

Publisher Rights Statement:

Freely available online through the PNAS open access option.

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



A subset of group A-like *var* genes encodes the malaria parasite ligands for binding to human brain endothelial cells

Antoine Claessens^a, Yvonne Adams^{a,1}, Ashfaq Ghumra^{a,1}, Gabriella Lindergard^a, Caitlin C. Buchan^a, Cheryl Andisi^b, Peter C. Bull^b, Sachel Mok^c, Archana P. Gupta^c, Christian W. Wang^d, Louise Turner^d, Mònica Arman^a, Ahmed Raza^a, Zbynek Bozdech^b, and J. Alexandra Rowe^{a,2}

^aCentre for Immunity, Infection and Evolution, Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh, EH9 3JT, United Kingdom; ^bKenya Medical Research Institute-Wellcome Laboratories, 80108 Kilifi, Kenya; ^cSchool of Biological Sciences, Nanyang Technological University, Republic of Singapore 637551; ^dCentre for Medical Parasitology, Department of International Health, Immunology, and Microbiology, Faculty of Health and Medical Science, University of Copenhagen, and Department of Infectious Diseases, Copenhagen University Hospital (Rigshospitalet), 1014 Copenhagen K, Denmark

Edited by Russell Howard, Oakbio Inc., Sunnyvale, CA, and accepted by the Editorial Board April 25, 2012 (received for review December 13, 2011)

Cerebral malaria is the most deadly manifestation of infection with *Plasmodium falciparum*. The pathology of cerebral malaria is characterized by the accumulation of infected erythrocytes (IEs) in the microvasculature of the brain caused by parasite adhesins on the surface of IEs binding to human receptors on microvascular endothelial cells. The parasite and host molecules involved in this interaction are unknown. We selected three *P. falciparum* strains (HB3, 3D7, and IT/FCR3) for binding to a human brain endothelial cell line (HBEC-5i). The whole transcriptome of isogenic pairs of selected and unselected parasites was analyzed using a variant surface antigen-supplemented microarray chip. After selection, the most highly and consistently up-regulated genes were a subset of group A-like *var* genes (*HB3var3*, *3D7_PFD0020c*, *ITvar7*, and *ITvar19*) that showed 11- to >100-fold increased transcription levels. These *var* genes encode *P. falciparum* erythrocyte membrane protein (PfEMP)1 variants with distinct N-terminal domain types (domain cassette 8 or domain cassette 13). Antibodies to HB3var3 and PFD0020c recognized the surface of live IEs and blocked binding to HBEC-5i, thereby confirming the adhesive function of these variants. The clinical in vivo relevance of the HBEC-selected parasites was supported by significantly higher surface recognition of HBEC-selected parasites compared with unselected parasites by antibodies from young African children suffering cerebral malaria (Mann-Whitney test, $P = 0.029$) but not by antibodies from controls with uncomplicated malaria (Mann-Whitney test, $P = 0.58$). This work describes a binding phenotype for virulence-associated group A *P. falciparum* erythrocyte membrane protein 1 variants and identifies targets for interventions to treat or prevent cerebral malaria.

adherence | pathogenesis | sequestration

Cerebral malaria (CM) is the most serious outcome of a *Plasmodium falciparum* infection, leading to death in 10–20% of cases and to long-term neurological deficits in others (1). The hallmark of the disease is microvascular sequestration, a process in which *P. falciparum*-infected erythrocytes (IEs) cytoadhere to endothelial cells, leading to microvascular obstruction, acidosis, hypoxia, and release of inflammatory cytokines (reviewed in ref. 2). Currently there is no specific treatment for CM other than standard antimalarial drugs and supportive therapies such as fluid replacement (3). The molecular mechanisms underlying CM are not understood, partly because of the lack of an appropriate animal model (4). However, human brain microvascular endothelial cell (HBEC) lines, such as HBEC-5i (5), can be used to study malaria host–parasite interactions, providing an in vitro model for CM (6–9). Despite the existence of this in vitro model, the parasite ligand(s) and host-cell receptor(s) mediating the interaction between IEs and brain endothelial cells remain unknown.

Previous work has identified variant surface antigens (VSA) such as *P. falciparum* erythrocyte membrane protein 1 (PfEMP1) as the parasite ligands mediating adhesion to a variety of receptors on human cells (10, 11). The PfEMP1 family is encoded by 50–60 *var* genes per parasite isolate (12). Although the sequence of each *var* gene is unique, all variants start with an N-terminal segment (NTS) and are followed by a succession of Duffy binding-like (DBL) and cysteine-rich interdomain region (CIDR) domains. These domains can be categorized into subtypes by the presence of short, conserved amino acid motifs, the rest of the sequence being highly polymorphic (13). The *var* gene family is subdivided into three main subgroups, A, B, and C, based on semiconserved upstream sequences (12). All group A *var* genes are located near the telomeres, all group C *var* genes are near the centromeres, and group B *var* genes can be found in either location. The *var* gene groups have functional and clinical significance. Group B and C *var* genes encode PfEMP1 variants that bind CD36 (14, 15) and are linked to nonvirulent clinical disease, whereas group A *var* genes encode non-CD36-binding variants linked to severe clinical disease including CM (16–19). Some group A *var* genes encode PfEMP1 variants that bind to uninfected erythrocytes to form rosettes (20–25); however, the adhesion phenotype of the majority of group A variants is unknown currently.

Although, because of their position on the surface of IEs, PfEMP1 encoded by *var* genes and other VSA such as rifins and stevors are the major candidates for parasite adhesion ligands, it remains possible that other parasite adhesins remain to be discovered. We investigated the whole transcriptome of parasites selected for binding to HBEC-5i cells to identify the parasite ligands for adhesion. We postulated that the parasite ligand(s) necessary

Author contributions: A.C., Z.B., P.C.B., and J.A.R. designed research; A.C., Y.A., A.G., G.L., C.C.B., C.A., S.M., A.P.G., C.W.W., M.A., and A.R. performed research; G.L., L.T., and Z.B. contributed new reagents/analytic tools; A.C., Y.A., A.G., G.L., C.C.B., C.A., P.C.B., S.M., A.P.G., C.W.W., M.A., and J.A.R. analyzed data; and A.C., Y.A., A.G., G.L., C.A., P.C.B., S.M., A.P.G., C.W.W., L.T., M.A., Z.B., and J.A.R. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission. R.H. is a guest editor invited by the Editorial Board.

Freely available online through the PNAS open access option.

Data deposition: The microarray data reported in this paper have been deposited in the Gene Expression Omnibus (GEO) database, www.ncbi.nlm.nih.gov/geo (accession no. GSE32211).

See Commentary on page 10130.

¹Y.A. and A.G. contributed equally to this work.

²To whom correspondence should be addressed. E-mail: Alex.Rowe@ed.ac.uk.

See Author Summary on page 10156 (volume 109, number 26).

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1120461109/-DCSupplemental.

for binding to HBEC-5i would be expressed at a higher level in selected (adherent) than in unselected (nonadherent) parasites and tested the hypothesis using microarray technology (25).

Results

Selection of *P. falciparum* for Binding to HBEC-5i. Preliminary experiments indicated that in vitro cultures of *P. falciparum* adhere poorly to HBEC-5i (Fig. 1A, Left). Four *P. falciparum* laboratory strains (HB3, 3D7, IT, and Dd2) were selected for binding to HBEC-5i cells by repeated panning (9). After five to seven rounds of selection, HBEC-5i-adherent lines were obtained from the HB3 (Fig. 1A, Right), 3D7, and IT strains. The *P. falciparum* strain Dd2 did not increase in adhesion to HBEC-5i cells even after five rounds of selection, suggesting that Dd2 lacks (or is unable to transcribe or transport) the necessary parasite ligand or that the lack of knobs in Dd2 prevents adhesion (26). HB3 was selected twice independently on HBEC-5i to provide a replicate for subsequent experiments (HB3-HBEC1 and 2). HB3 also was selected on TNF-activated HBEC-5i (HB3-HBEC-TNF) to investigate whether different parasite ligands would be selected on cytokine-stimulated and resting endothelial cells.

To assess the relevance of HBEC-5i selection for primary human tissues, HB3-HBEC parasites were tested for adhesion to primary endothelial cells derived from brain, dermal, and lung tissues (ScienCell). In all cases the selected parasites showed enhanced binding to primary endothelial cells (>10-fold greater adhesion of selected than unselected parasites) (Fig. 1B). Fur-

thermore, HBEC-5i-binding IEs that were physically detached from HBEC-5i cells and then incubated with other endothelial cell lines showed strong binding (Fig. 1C), excluding the possibility that subpopulations of parasites bound to the different cell lines. These data show that the HBEC-5i-selected phenotype is relevant for primary human tissues and indicates that the host receptor is present on endothelia from diverse sources, consistent with sequestration of IEs in multiple endothelial beds in CM patients in vivo (27). Neither unselected nor HB3-HBEC-selected parasite lines bound above background levels to COS-7 cells, showing that the selected parasites do not bind nonspecifically to all cell types.

Adhesion Phenotype of HBEC-5i-Selected Parasites. The other adhesion properties of the selected parasites were examined. The selected lines from all three strains did not form rosettes (SI Appendix, Fig. S1A), and platelet-mediated clumping was reduced significantly after selection for HBEC-5i binding (SI Appendix, Fig. S1B). HB3-HBEC-selected parasites showed significantly lower binding to CD36 and ICAM-1 than did HB3-unselected parasites (SI Appendix, Fig. S1C), and there was no increase in binding to any known *P. falciparum* adhesion receptor, including fractalkine, PECAM-1, P-selectin, E-selectin, VCAM-1, integrin $\alpha V\beta 3$, thrombospondin, NCAM, fibronectin, heparin, chondroitin sulfate A, hyaluronic acid, gC1qR, or heparan sulfate (SI Appendix, Fig. S1C and Table S1). IT-HBEC-selected parasites also showed significantly lower binding to CD36 than did IT-unselected parasites, and the only minor but statistically significant increase was in binding to gC1qR (SI Appendix, Fig. S1D), although absolute levels of binding remained low. gC1qR has been implicated primarily as a platelet-mediated clumping receptor for *P. falciparum*, although it also is expressed on endothelial cells (28). IT-HBEC parasites had a clumping frequency of <2%; therefore it seems unlikely that gC1qR is a major receptor for these parasites. Adhesion-blocking antibodies to CD36 (29) and ICAM-1 (30) had no effect on binding of HBEC-selected parasites to HBEC-5i (SI Appendix, Fig. S1E), thus further excluding a role for these receptors in HBEC-5i binding. Therefore we were unable to identify the HBEC-5i receptor(s) used by the HBEC-selected parasite lines, and HBEC-5i binding may involve an unknown host endothelial receptor.

We also examined knob positivity in the selected and unselected parasite lines, because lack of knobs is known to influence parasite adhesion properties (26). We found that the percentage of knob-positive IEs in the selected and unselected lines of each strain did not differ significantly (mean percent of knob-positive IE (SE) for HB3-HBEC-selected, 62.5 (2.3) and -unselected, 65.0 (1.7), $P = 0.41$; IT-HBEC-selected, 69.3 (2.5) and -unselected, 68.3 (2.7), $P = 0.79$; 3D7-HBEC-selected, 54.0 (1.5) and -unselected, 55.5 (1.7), $P = 0.53$; unpaired t test in each case). Therefore, the presence or absence of knobs is unlikely to explain the differences in HBEC-5i adhesion between the selected and unselected parasite strains.

Whole-Transcriptome Analysis Identifies a Subset of Group A *var* Genes as Being Highly Transcribed in HBEC-5i-Selected Parasites.

We used a VSA-supplemented microarray chip to examine the whole transcriptome of selected and unselected parasites, with the aim of identifying candidate parasite adhesion ligands as gene(s) whose transcriptional levels increased markedly after selection (25). The VSA-supplemented chip contains oligonucleotide probes for all the VSA genes (*var*, *rif*, and *stevor*) from the HB3, IT, and Dd2 strains (25) added to the existing 3D7-based chip (31). Isogenic pairs of selected and unselected *P. falciparum* parasite cultures were synchronized (SI Appendix, Table S2), and RNA samples were collected every 8 h for 48 h. The selected and unselected parasites were at similar levels of maturity during the time-course experiment, as shown by Giemsa smear (SI Appendix, Fig. S2) and by strongly positive Pearson




Fig. 1. Selection of *P. falciparum* IEs for adhesion to HBMEC. (A) Unselected *P. falciparum* lines (e.g., HB3 shown here) show only minimal binding to HBEC-5i cells (Left). After five rounds of panning, adherent parasites are selected (Right). The cells were fixed with glutaraldehyde, stained with Giemsa, and visualized by microscopy at 1,000 \times magnification. (B) Binding of selected (HB3-HBEC) and unselected (HB3-Uns) parasite lines to primary endothelial cells from human brain (HBMEC), skin (HDMEC), and lung (HPMEC). Means + SE from triplicate wells are shown. (C) Rebinding of HBEC-5i-adherent IEs that were detached mechanically from HBEC-5i cells and then reincubated with HBEC-5i cells (positive control), HDMEC, or HPMEC.

correlation coefficients when data from all oligonucleotide probes at each time point for selected and unselected parasites were compared (SI Appendix, Fig. S3; see exceptions for time point 3 of HB3-HBEC-TNF and time point 6 of IT-HBEC, whose data should be interpreted with caution).

The level of transcription of each gene in selected parasites was compared with that in unselected parasites and was expressed as a fold expression ratio. In HB3, the gene with the most markedly and consistently increased transcription in selected parasites was a group A *var* gene, *HB3var3* (Fig. 2A–D and G). There were five oligonucleotide probes on the microarray chip for this gene, and all five showed strongly increased hybridization signals in HB3-HBEC1 and HB3-HBEC2 compared with unselected HB3 (Fig. 2B and C). Taking an average of all five probes, *HB3var3* was up-regulated in selected parasites by up to 61-fold (Fig. 2G). (By “up-regulated” we mean that the amount of mRNA for a particular gene was increased in selected compared with unselected parasites.) Selection of HB3 parasites on TNF-activated HBEC-5i also resulted in a parasite population with increased transcription of *HB3var3* (Fig. 2D and G). Multiple other *var* genes were up-regulated at time point 3 in the parasites selected on TNF-activated HBEC-5i, but the upregulation of these genes may have been caused by poor synchronization between selected and unselected parasites at this time point (SI Appendix, Fig. S3).

In 3D7, a single group A *var* gene, *PFD0020c*, showed the most marked and consistent increase in transcription after selection (Fig. 2E and G). All six oligonucleotide probes to *PFD0020c* showed a similar pattern. In the IT strain, two *var* genes, *ITvar7* (group A) and *ITvar19* (group B), showed highly increased transcription after selection (Fig. 2F). The five probes specific to each of these two genes showed, on average, an up-regulation of 10- to more than 100-fold (Fig. 2G).

When the five selections are considered together, the microarray data for the *var* gene family are striking. In all five selections, one or two *var* genes show markedly increased transcription in the selected parasites, but multiple other *var* genes are down-regulated. At time point 3 (16–24 h postinvasion), there is an 11- to 320-fold increase in *HB3var3*, *PFD0020c*, *ITvar9*, and *ITvar19* in the selected populations (Fig. 2G). No other *var* gene was up-regulated by more than twofold across more than one time point.

Quantitative real-time PCR (qPCR) with specific primers to the *var* genes of each parasite strain confirmed the up-regulation detected by microarray (Fig. 2G) and did not detect any other up-regulated *var* genes. Expression profiling by RT-PCR with universal primers to the *var* gene DBL α region (32, 33) also identified the same set of up-regulated *var* genes (SI Appendix, Fig. S4A–D), confirming that all three methods are comparable. RT-PCR experiments on HB3 parasites selected for binding to human dermal microvascular endothelial cells (HDMEC) and human pulmonary microvascular endothelial cells (HPMEC) showed that the group A *var* gene up-regulated with HBEC-5i (*HB3var3*) also was up-regulated following selection on other endothelial types (SI Appendix, Fig. S4E).

Rif Genes Located Head-to-Head with the *var* Gene Ligand Candidates Are Up-Regulated. In the *rif* family, three genes showed increased transcription by threefold or more in at least one time point in all three HB3 selections (Fig. 3A). Only one of these genes, *HB3RifA_081*, showed a substantial, eight- to 100-fold increase (Fig. 3B). Interestingly, this *rif* gene is located next to *HB3var3*, on the opposite strand, and is transcribed in the opposite direction. Thus, the selection of HB3 parasites on HBEC-5i, with or without prior activation with TNF, led to the increased transcription of *HB3var3* and its “head-to-head” *HB3RifA_081* gene. No *stevor* gene was up-regulated by threefold or more in all three HB3-derived selections.

In 3D7-HBEC, the most highly up-regulated *rif* gene was *PFD0025w* (Fig. 3B and SI Appendix, Fig. S5A). Again, this *rif*

gene is located head-to-head with the most highly transcribed *var* gene, *PFD0020c*. Several other *rif* genes and four *stevor* genes showed more than threefold up-regulation in at least one time point (SI Appendix, Fig. S5A). These data are each based on a single probe (because of the small size of *rif* and *stevor* genes) and a single experiment; therefore further replicates would be required to determine whether these increases are consistent. In IT-HBEC, five *rif* genes and one *stevor* gene showed more than threefold up-regulation in a single time point (SI Appendix, Fig. S5B). No expression data were available for *IT4rifA_044*, the *rif* gene found head to head with *ITvar7*. This lack of data may mean that this gene is not transcribed above background levels in one of the parasite populations or could be the result of a technical problem, such as misprinting of the oligonucleotide probe. The other up-regulated *var* gene in IT parasites, *ITvar19*, does not have a head-to-head *rif* gene, because these head-to-head arrangements are found only with group A *var* genes.

To confirm the up-regulation of the specific head-to-head *rif* genes in the HB3 and 3D7 strains, and to examine further the transcription of *IT4rifA_044*, the *rif* gene found head-to-head with *ITvar7*, we carried out real-time qPCR with *rif*-specific primers (34). This evaluation confirmed the up-regulation of *HB3RifA_081* in HB3-selected parasites and *PFD0025w* in 3D7-selected parasites (Fig. 3B). Furthermore, the data showed a 446-fold increase in *IT4rifA_044* in IT-selected parasites (Fig. 3B).

Taken together, these data indicate that selection for binding to HBEC-5i leads to increased transcription of specific group A *var* genes and that the *rif* genes located head-to-head with these *var* genes are up-regulated also. Therefore, the genes *HB3RifA_081*, *PFD0025w*, and *IT4rifA_044* also should be considered as encoding potential parasite ligands for HBEC-5i binding, given the known location of rifins on the surface of IEs (35).

Some Exported Proteins Show Increased Transcription in HBEC-Selected Parasites. The four *var* genes identified above and their accompanying *rif* genes are by far the most highly and consistently up-regulated genes after selection. However, other non-VSA genes could be involved in cytoadherence to HBEC-5i. The vast majority of non-VSA genes have a sequence that is virtually identical from one strain to another; therefore the three strains (HB3, 3D7, and IT) can be considered as replicates of each other (36). Using the arbitrary cutoff of a twofold increase in at least one time point, 15 non-VSA genes were found to be up-regulated, and 58 non-VSA genes were down-regulated in all five selections (SI Appendix, Figs. S6 and S7). No specific functional pathways were statistically significantly up-regulated by functional enrichment analysis. Furthermore, no non-VSA genes showed increases in transcription comparable in intensity or consistency to the up-regulated *var* genes (SI Appendix, Fig. S6 and Fig. 2). Only one gene was up-regulated by at least threefold in all five selections: *PF14_0472*, a member of the Plasmodium helical interspersed subtelomeric (PHISTa) family (37). Six other up-regulated genes encode proteins predicted or proven to be exported: *P. falciparum* erythrocyte membrane protein 3 (*PfEMP3*) (38), ring-IE surface antigen (*RESA-1*) (39), membrane associated histine-rich protein 1 (*MAHRP-1*) (40), and three others with a Pexel motif: *PF14_0740*, *PF11_0035*, and *PFF0055w* (37). These six genes and *PF14_0472* are up-regulated at time point 3 (16–24 h postinvasion) in almost all selections, indicating that they could be translated in time for cytoadherence at the pigmented trophozoite stage.

Of the 58 down-regulated genes, 11 were down-regulated by at least threefold in at least one time point (SI Appendix, Fig. S7). Intriguingly, 41 of the 58 down-regulated genes encode proteins proven or predicted to be involved with merozoite invasion. Indeed, a functional enrichment analysis revealed the merozoite invasion pathway to be highly enriched ($P \sim 0$) (SI Appendix, Table S3). In other words, the selection of parasites for binding to HBEC-5i resulted in a statistically highly significant decrease




Fig. 3. The *rif* genes located head-to-head with the up-regulated *var* genes are up-regulated also. (A) HB3 *rif* genes up-regulated by at least threefold in all HB3-derived strains. Because of the small size of *rif* genes (1–2 kbp), there was only one oligonucleotide probe per gene on the microarray chip. Color scale is as in Fig. 2. (B) Expression fold ratios of the *rif* genes located head-to-head with the most up-regulated *var* genes in each selection. The last column indicates real-time qPCR data, obtained from RNA at late ring stage. NA, not available (i.e., no transcription above background level was detected in at least one parasite population); ND, not determined.

Taken together, examination of the entire transcriptome of three *P. falciparum* strains selected for adhesion to HBEC-5i identifies a subset of group A *var* genes and their head-to-head *rif* genes as the most likely candidates for adhesion ligands because of their markedly increased transcription after selection.

Up-Regulated *Var* Genes Show Similarities in PfEMP1 Architecture. Examination of the *var* genes up-regulated in HBEC-5i-selected parasites reveals that they encode PfEMP1 variants that are diverse in sequence (32–46% amino acid identity between each pair) (SI Appendix, Table S4). However, the up-regulated variants do show similarities in PfEMP1 architecture (Fig. 4). As expected for group A *var* genes, *HB3var3*, *PFD0020c*, and *ITvar7*, all encode variants with a DBL α 1 domain at the N-terminus, whereas the group B *ITvar19* variant has a DBL α 2 domain (Fig. 4). Despite its group B upstream region, the *ITvar19*-encoded




Fig. 4. PfEMP1 architecture of variants up-regulated after HBEC-5i selection. ATS, acidic terminal segment; CIDR, cysteine-rich interdomain region; DBL, Duffy binding-like domain; DC13, domain cassette 13; DC8, domain cassette 8; NTS, N-terminal segment. Pairwise amino acid identities between domains are shown in SI Appendix, Tables S4 and S5.

variant has some group A-like features: It is large (with seven extracellular domains, compared with four for a typical group B variant) and has a CIDR α 1 domain (usually found in group A variants). The presence of the CIDR α 1 domain, which is uncommon (present in <10% of all *var* genes) is the most obvious distinguishing feature of the four adhesion ligand candidates. DBL α 1 and CIDR α 1 domains recently have been classified into subgroups on the basis of sequence homology (41). Both *HB3var3* and *ITvar7* have the N-terminal domain pair DBL α 1.7/CIDR α 1.4, also known as “domain cassette (DC) 13.” [Domain cassettes are sets of PfEMP1 domains that usually occur together (41).] Of seven *P. falciparum* strains whose *var* gene repertoires have been fully sequenced and classified, most strains have only one variant with DC13, and these variants are all group A *var* genes that show PfEMP1 architecture similar to that of *HB3var3* and *ITvar7* (41). Thus, DC13-type variants, including *HB3var3* and *ITvar7*, may represent functionally similar alleles in different parasite strains. PFD0020c and *ITvar19* have different DBL α types, but they share very similar CIDR α 1.1 domains with 74% amino acid identity (but only 39–43% identity with CIDR α 1.4 of *HB3var3* and *ITvar7*) (SI Appendix, Table S4). Other sequenced strains usually have only one variant with a CIDR α 1.1 domain, and most of these strains are group B PfEMP1 variants with PfEMP1 architecture similar to that in *ITvar19*, represented by DC8 (41). PFD0020c has three of the four domains usually found in DC8, differing only in the first DBL domain (Fig. 4).

The *HB3var3* variant is identical to *HB3var5* from the DBL γ domain to the end of the extracellular region. The fact that *HB3var3* but not *HB3var5* was up-regulated after selection for binding to HBEC-5i suggests that the functional binding region includes the first three domains (NTS-DBL α -CIDR α -DBL β) that differ in *HB3var3* and *HB3var5*.

Antibodies Against *HB3var3* Inhibit Adhesion of HB3-HBEC to HBEC-5i. The transcriptional patterns shown above combined with the known adhesion properties of PfEMP1 make the PfEMP1 variants encoded by *HB3var3*, *PFD0020c*, *ITvar7*, and *ITvar19* the most likely candidate parasite adhesion ligands for HBEC-5i binding. To test the hypothesis that this subset of group A-like *var* genes encodes the parasite ligands for adhesion to HBEC-5i, we raised antibodies to specific PfEMP1 domains.

The NTS-DBL α 1 and the NTS-DBL α 1-CIDR α 1 (hereafter called the “di-domain”) from *HB3var3* were expressed as recombinant proteins in *Escherichia coli*. For NTS-DBL α 1, the recombinant protein was mostly of the expected molecular weight (54.1 kDa) and showed a shift upon reduction, indicating the presence of disulfide bonds in the recombinant protein (Fig. 5A, Left). For the di-domain, much of the protein was degraded, although some protein at the expected molecular weight (88.2




Fig. 5. Antibodies against HB3var3 inhibit adhesion of HB3-HBEC to HBEC-5i cells. (A) SDS/PAGE showing recombinant NTS-DBL α 1 and di-domain (NTS-DBL α 1-CIDR α 1) domains from HB3var3 expressed in *E. coli*. (B) Immunofluorescence assay with antisera to HB3var3 (1/100 dilution) showing punctate surface fluorescence on live IEs. IEs are shown by DAPI staining of the parasite nuclei. PfEMP1 antibody was detected with highly cross-absorbed goat anti-rabbit IgG Alexa Fluor 488 (1/1,000). (C) Titration of anti-HB3var3 antibodies (purified total IgG) against live HB3-HBEC IEs by flow cytometry. (D) Inhibition of HB3-HBEC binding to HBEC-5i cells by antibodies to HB3var3 NTS-DBL α 1 and di-domain. Means and SD from quadruplicate wells of a representative experiment are shown. Binding is compared with control wells with no added IgG. Negative controls are nonimmunized rabbit IgG and IgG raised to the NTS-DBL α 1 domain of a rosette-mediating group A PfEMP1 variant (HB3var6). A significant decrease in adhesion was seen in the presence of HB3var3 antibodies (P < 0.0001, ANOVA). *** P < 0.001, * P < 0.05, Tukey's multiple comparison test. (E) Inhibition of HB3-HBEC binding to HBEC-5i cells by antibodies to HB3var3 DBL δ 5. Mean and SE from three independent experiments are shown. Binding is compared with control wells with no added IgG. The negative control is preimmune serum from the rabbit used to raise DBL δ 5 antibodies. A significant decrease in adhesion was seen in the presence of HB3var3 antibodies (P < 0.0001, ANOVA). * P < 0.05, *** P < 0.001, Tukey's multiple comparison test.

kDa), and which showed a shift upon reduction, was obtained (Fig. 5A, Right).

Antisera to HB3var3 NTS-DBL α 1 and the di-domain showed punctate surface fluorescence of live HB3-HBEC IEs by immunofluorescence assay (IFA) (Fig. 5B) typical of PfEMP1 antibodies (23). Rabbit preimmune sera and nonimmunized rabbit control sera were negative by IFA. Total IgG were purified from the antiserum and used at fourfold dilutions in flow cytometry to determine the end titer (here defined as the lowest concentration of total IgG to stain in >50% of live IEs). The HB3var3 NTS-DBL α 1 antibodies gave surface reactivity down to 0.39 μ g/mL of total IgG (Fig. 5C), and the di-domain antibodies gave surface reactivity down to 1.56 μ g/mL of total IgG. The HB3var3 NTS-DBL α 1 antibodies were tested at 400 μ g/mL for live IE surface reactivity with other *P. falciparum* strains selected for a range of

different adhesion phenotypes (24). The antibodies did not show surface reactivity with HB3-unselected parasites, 3D7-HBEC, 3D7-unselected, IT-HBEC, IT-unselected, six *P. falciparum* rosetting strains, or 12 clinical isolates (data are shown in figures 4b and 6a of ref. 24, in which the non-Ros group A control is HB3var3 NTS-DBL α 1 antibody). Therefore, the HB3var3 NTS-DBL α 1 antibodies are highly variant- and strain-specific and show surface reactivity only with the homologous parasite line HB3-HBEC expressing the HB3var3 PfEMP1 variant.

To determine whether the HB3var3 PfEMP1 variant is the parasite ligand for binding to HBEC-5i, the effect of HB3var3 antibodies on adhesion was examined. Both NTS-DBL α 1 and di-domain antibodies inhibited binding to HBEC-5i compared with control nonimmunized rabbit IgG (Fig. 5D). Polyclonal rabbit IgG raised against a PfEMP1 variant not involved in HBEC-binding

(against the NTS-DBL α 1 domain of the rosette-mediating HB3var6 group A PfEMP1 variant) (24) showed no inhibition of binding (Fig. 5D). We also tested antiserum raised against another recombinant domain of the HB3var3 variant (DBL δ 5) produced in baculovirus (42). Previous work has shown that antibodies to multiple PfEMP1 domains are able to block adhesion in the case of rosetting parasites (23). The HB3var3 DBL δ 5 antiserum showed punctate surface fluorescence with live IEs of HB3-HBEC parasites at 1/25 and 1/100 dilution, whereas the preimmune serum was negative at the same concentrations. The antiserum was negative by IFA against HB3-unselected, 3D7-HBEC, 3D7-unselected, IT-HBEC, and IT-unselected parasites. The antiserum to HB3var3 DBL δ 5 showed specific inhibition of adhesion of HB3-HBEC IEs to HBEC-5i, although it was not as effective as NTS-DBL α 1 antibody (Fig. 5E). Therefore, three different antibody preparations against two distinct domains of the HB3var3 PfEMP1 variant inhibited binding of HB3-HBEC to HBEC5i, confirming that HB3var3 is a parasite adhesion ligand and making it extremely unlikely that antibody cross-reactivity with other molecules on the surface of IEs is responsible for the data shown. None of the antibodies caused agglutination of IEs at the concentrations used in the adhesion inhibition assays.

Antibodies to two distinct domains of the PfEMP1 variant up-regulated in 3D7 parasites, PFD0020c, also were tested for adhesion inhibition. Antibodies to the NTS-DBL α 1 domain of PFD0020c (produced in *E. coli*) gave punctate surface fluorescence of 3D7-HBEC live IEs down to 6.25 μ g/mL of total IgG, whereas antibodies to DBL γ 6 (produced in *Baculovirus*) gave surface reactivity down to 100 μ g/mL. Both antibodies were variant- and strain-specific and did not show surface reactivity with the IT- or HB3-HBEC-selected or -unselected parasite lines when tested at 400 μ g/mL. The NTS-DBL α 1 antibodies inhibited binding of 3D7-HBEC to HBEC-5i by 52% compared with rabbit IgG control at 50 μ g/mL of total IgG, whereas the DBL γ 6 antibodies inhibited binding by 64% compared with rabbit IgG control at 250 μ g/mL of total IgG ($P < 0.001$, paired *t* test). Therefore, for PFD0020c, two independent antibody preparations to separate domains show variant- and strain-specific surface reactivity and inhibit adhesion of 3D7-HBEC to HBEC-5i, providing evidence that the PFD0020c PfEMP1 variant is the parasite adhesion ligand.

In Vivo Significance of the HBEC-5i-Binding Subset of Group A PfEMP1 Variants. No animal model adequately reflects the pathology and clinical features of severe *P. falciparum* malaria in humans; therefore, it is not possible to test directly whether HBEC-5i-selected parasites cause CM. As an alternative approach to examine the in vivo significance of the HBEC-5i-binding variants, we investigated whether African children suffering from CM develop antibodies that recognize the HBEC-selected parasite lines. Plasma samples from acutely ill or convalescent Kenyan children with CM or uncomplicated malaria (UM) were used to assess surface recognition of live IEs from selected and unselected parasites by flow cytometry. Acute plasma samples collected from both clinical groups at the time of hospital admission (predominantly reflecting prior exposure) showed no significant difference in their reactivity with selected or unselected parasite lines (Fig. 6A and B). However, plasma samples from convalescent patients with CM (reflecting antibody responses to the variant causing the clinical episode) showed significantly greater recognition of the HBEC-selected lines than of the unselected lines (Fig. 6C). In contrast, plasma samples from convalescent patients with UM did not show differential reactivity with HBEC-selected lines compared with -unselected lines (Fig. 6D), although surface reactivity against both HBEC-selected and -unselected lines increased compared with the samples from acutely ill patients (Fig. 6B and D). When each parasite strain was considered individually, all three strains showed a trend toward increased recognition of




Fig. 6. Recognition of HBEC-selected and -unselected parasites lines by antibodies from African malaria patients. Acute and convalescent plasma samples were collected from 10 patients with CM and 10 age- and date of admission-matched patients with UM. Surface recognition of HBEC-selected and -unselected (unsel) parasite lines was tested by flow cytometry. The mean fluorescence intensity (MFI) of the uninfected erythrocyte population was subtracted from the MFI of the IE population to give the specific MFI of the IE population shown on the y axis. Each data point represents plasma from one patient. The median of the values from the three individual strains was used to represent the specific recognition of HBEC-selected or -unselected parasites by each plasma sample (the individual strains are shown in *SI Appendix*, Fig. S8). (A) Acute plasma from patients with CM. (B) Acute plasma from patients with UM. (C) Convalescent plasma from patients with CM. (D) Convalescent plasma from patients with UM. IQR, interquartile range.

HBEC-selected compared with -unselected parasites in sera from convalescent patients with CM, but the increase was statistically significant only in the 3D7 strain (*SI Appendix*, Fig. S8).

Discussion

In this work we found that a distinct subset of group A-like *var* genes was highly transcribed in three *P. falciparum* strains selected for adhesion to an HBEC line (Fig. 2). The up-regulated genes encode PfEMP1 variants with similar domain structures exemplified by the presence of DC8 (3D7_PFD0020c and ITvar19) or DC13 (HB3var3 and ITvar7) (Fig. 4). In their companion articles, Avril et al. (43) provide independent confirmation of the up-regulation of DC8 genes following selection on brain endothelial cells, and Lavstsen et al. (44) show DC8 and DC13 genes to be highly differentially transcribed in patients with severe malaria compared with UM controls, confirming the clinical importance of DC8- and DC13-expressing parasites. DC8 genes were differentially transcribed in all clinical forms of severe malaria (CM, severe malarial anemia, and respiratory distress), consistent with our findings and those of Avril et al. (43) that parasites selected for binding to HBEC-5i also could adhere to other primary endothelial cell types, giving the potential to sequester at multiple sites throughout the body in addition to the brain. Taken together, these three studies identify parasites expressing DC8 and DC13 as having high potential for cytoadherence to endothelial cells in the brain and elsewhere and

suggest that DC8 and DC13 PfEMP1 variants may be important targets for interventions to treat or prevent severe malaria.

To confirm the role of DC8 and DC13 PfEMP1 variants in binding to HBEC-5i, we raised antibodies to domains of HB3var3 and 3D7_PFD0020. In each case antibodies to two distinct domains showed variant- and strain-specific reactivity with the surface of live IEs and blocked binding of IEs to HBEC-5i (Fig. 5). These data strongly support the identification of the HB3var3 and PFD0020c PfEMP1 variants as parasite adhesion ligands for HBEC-5i binding.

Our examination of the whole transcriptome of three parasite strains showed that the only other highly up-regulated genes after selection for HBEC-5i binding were the *rif* genes located head-to-head with the up-regulated group A *var* genes (Fig. 3). Given the known location of rifins on the surface of IEs (35), it is possible that the rifins could contribute to host cell binding; further experiments will be required to test this possibility. An alternative hypothesis is that the *rif* genes are up-regulated because their transcriptional pattern is linked to the adjacent head-to-head *var* gene. The coregulation of group A *var* genes and their adjacent *rif* genes has been reported previously (34, 45) and also was seen in our proof-of-concept experiment for the VSA-supplemented microarray with rosetting parasites (25).

The microarray approach has the potential to reveal non-VSA genes that could be involved directly or indirectly in cytoadherence, for example by contributing to the trafficking of PfEMP1 to the IE surface. We found only 15 non-VSA genes that were up-regulated by twofold or more in all selections; among these genes were several encoding proteins predicted to be exported into the infected red blood cell cytoplasm (SI Appendix, Fig. S6). Two of these genes, MAHRP-1 and PF14_0752 (PHISTa), also were modestly up-regulated in IT parasites selected for rosetting (25). An indirect role for MAHRP-1 in cytoadherence already had been demonstrated, because deletion of the gene leads to depletion of surface-exposed PfEMP1 (46). PF14_0752 is part of the PHISTa subfamily, whose members are specific to *P. falciparum* (37). PF14_0752 was one of the most highly up-regulated genes in CD36-selected parasites (47), in field isolates (48), and in 3D7 gametocytes (49). Recently a PHISTc family member was shown to bind to the intracellular domain of PfEMP1 (50); however the function of other PHIST family members is unknown and awaits further research.

One of the attractions of the microarray approach is its potential to reveal previously unrecognized parasite adhesion proteins. At first sight, to conclude that the major adhesion ligands are PfEMP1 variants, with a possible contribution from rifins, could be considered disappointing. Similarly, our previous microarray study of rosetting parasites confirmed the marked transcriptional up-regulation of the known parasite rosetting ligand, the PfEMP1 variant encoded by *ITvar9* (20), and did not identify any strong alternative candidates (25). However, we suggest that these data, rather than being disappointing, are important precisely because they provide a convincing demonstration of the importance of PfEMP1 in parasite adhesion that is based on global transcriptional data rather than relying solely on the examination of individual genes and gene families that has characterized previous work.

The demonstration here of up-regulation of a subset of group A-like *var* genes in HBEC-5i-selected parasites fits well with a body of previous work on *var* gene transcription in *P. falciparum* clinical isolates as well as the companion article by Lavstsen et al. (44). The majority of studies addressing the relationship between *var* genes and clinical disease have found an association between group A *var* gene transcription and severe malaria or CM (16–19, 51). Previously, the only known binding phenotype for group A PfEMP1 variants was rosetting (20–23), with two group A domain cassettes (DC11 and DC16) being linked to rosette formation (24). DC16 was not associated with severe malaria in the study by Lavstsen et al. (44) and DC11 was not

tested. DC11 is linked to IgM-positive rosetting (24), which probably is the most clinically important rosetting phenotype (52). Further research will be required to study the association between DC11 variants and severe malaria.

ICAM-1 often is cited as an endothelial receptor involved in CM (53); however, its precise role remains uncertain, because several studies show no significant increase in ICAM-1 binding in parasite isolates from patients with CM as compared with controls (54–56). Furthermore, a human ICAM-1 polymorphism that occurs at high frequency in Africa (57) and reduces the ability of *P. falciparum* to bind to ICAM-1 (53, 58) does not protect against CM or severe malaria (59). In the work shown here, although ICAM-1 is expressed on the surface of HBEC-5i, it is not the receptor used by the HBEC-selected parasites because (i) in spot-binding assays HBEC-selected parasites did not show increased binding to recombinant ICAM-1 compared with unselected parasites (SI Appendix, Fig. S1 C and D); (ii) ICAM-1 antibodies did not block adhesion of selected parasites to HBEC-5i (SI Appendix, Fig. S1E); and (iii) IT-HBEC parasites express *ITvar7* and *ITvar19*, which have been shown to be ICAM-1 nonbinders (60). The endothelial receptor(s) used by the HBEC-5i-selected parasites are currently unknown.

In conclusion, we show that the *P. falciparum* ligands for adhesion to HBEC-5i are a subset of group A-like PfEMP1 variants (DC8 and DC13 type). The clinical relevance of these variants was shown by recognition of HBEC-selected lines by sera from children recovering from CM, thus validating the interaction with HBEC-5i as an in vitro model for CM sequestration. The DC8 and DC13 PfEMP1 variants represent potential targets for interventions to prevent or treat CM.

Materials and Methods

Please see SI Appendix, Text for the materials and methods related to the adhesion properties of selected and unselected parasite lines; microarray hybridizations; real-time qPCR; the generation of polyclonal antibodies to HB3var3 NTS-DBL α 1, HB3var3 di-domain, and 3D7 PFD0020c NTS-DBL α 1; the generation of polyclonal antibodies to HB3var3 DBL65 and 3D7 PFD0020c DBL76; and flow cytometry with plasma from African children.

Parasite and Human Endothelial Cell Culture. *P. falciparum* strains HB3, 3D7, IT/FCR3, and Dd2 were cultured in supplemented RPMI medium as described (61). The HBEC-5i cell line is an immortalized endothelial line described previously (5). HBEC-5i cells were grown in DMEM/F-12 medium (Sigma) supplemented with 2 mM L-glutamine, endothelial cell growth supplement (5 mL of 100 \times per 500 mL of medium, hereafter referred as “incomplete medium”) (ScienCell), and 10% vol/vol heat-inactivated bovine serum. Parasite strains were selected by panning as described in detail previously (9). For HB3-HBEC-TNF, HBEC-5i cells were activated 24 h before selection by addition of TNF α at 50 μ g/mL. HBMEC, HDMEC, and HPMEC (all from ScienCell) were cultured as for HBEC-5i cells, except for the use of endothelial cell medium (ScienCell) and bovine serum at 5% vol/vol, following the manufacturer’s instructions.

Binding Assays on Endothelial Cells. The day before the assay, endothelial cells were plated on fibronectin-coated eight-well chamber slides (BioCoat 354628; BD) at 10⁴ cells per well. For each assay, at least two replicate wells per slide were used. Parasite cultures were washed twice with incomplete medium. Two hundred microliters of parasite culture (pigmented trophozoites at 5–10% parasitemia and 2% hematocrit) in incomplete DMEM/1% BSA were added per well. The slide was incubated for 75 min at 37 °C with gentle resuspension of cells halfway through the incubation. The chamber then was removed according to the manufacturer’s instructions. The slide was washed in a 100-mm Petri dish (351029; BD) filled with incomplete DMEM. The slide was held still using tweezers, and the dish was rocked gently. This step was repeated four times, each time in a new dish with fresh medium. The slide was checked under an inverted microscope to ensure there were no or few unbound cells remaining. It then was fixed and stained with 1% glutaraldehyde for at least 1 h and was stained with 5% vol/vol Giemsa for 20 min. IEs bound to at least 100 isolated cells were counted by light microscopy using the 100 \times objective. For rebinding assays, after the washing step, bound IEs were detached by flushing the cell surface with incomplete DMEM using a Pasteur

pipette at least 10 times. IEs were placed in a 15-mL tube and centrifuged at $300 \times g$ for 5 min. They were resuspended with 200 μ L of incomplete DMEM per well and then were reincubated on endothelial cells as above.

IFA and Flow Cytometry with Antibodies to PfEMP1. IFA with rabbit pre-immune and immune sera and live IEs were carried out as described (23). For each antigen, the rabbit serum giving the brightest IFA signal with the lowest background was chosen for purification of total IgG. Staining for flow cytometry was carried out as for IFA except that all incubations included 1.25 μ g/mL Hoechst (instead of DAPI) to stain parasite nuclei. After the secondary incubation (1:1,000 of a highly cross-absorbed Alexa Fluor 488 goat anti-rabbit IgG) (Invitrogen) and washes, cells were fixed in 0.5% paraformaldehyde on ice for 20 min and washed twice in FACS buffer (PBS/0.1% BSA/0.1% sodium azide). Cells were resuspended in 500 μ L of FACS buffer and analyzed on a Becton-Dickinson LSRII flow cytometer by counting 500,000 events.

Antibody Inhibition of Binding to HBEC-5i Cells. Binding assays were carried out as described above, with a preincubation step in which the culture suspension

(5–10% parasitemia and 2% hematocrit in incomplete DMEM/1% BSA) was incubated for 20 min with antibodies to PfEMP1 or controls (concentrations are shown in figure legends). Two hundred microliters of this suspension were added per well on the endothelial cell culture slide, and the assay was completed as described above. Binding was compared with control wells with no added IgG. All antibodies were tested in at least three independent experiments with at least triplicate wells per antibody in each experiment.

Statistical Analysis. Graphs and statistical analysis were carried out using GraphPad Prism software (GraphPad).

ACKNOWLEDGMENTS. This work was funded by the Wellcome Trust through a 4-y doctoral studentship (to A.C.), a Senior Fellowship in Basic Biomedical Science (to J.A.R.), Grant 084226, a Strategic Award (Grant 084538 to C.A.), and Wellcome Trust Programme Grants 084535 and 077092 (to P.C.B.). C.W.W. and L.T. were supported by Danish Medical Research Council Grant 271-08-0540. This paper was submitted with the permission of the director of the Kenya Medical Research Institute.

- Idro R, Marsh K, John CC, Newton CR (2010) Cerebral malaria: Mechanisms of brain injury and strategies for improved neurocognitive outcome. *Pediatr Res* 68:267–274.
- van der Heyde HC, Nolan J, Combes V, Gramaglia I, Grau GE (2006) A unified hypothesis for the genesis of cerebral malaria: Sequestration, inflammation and hemostasis leading to microcirculatory dysfunction. *Trends Parasitol* 22:503–508.
- Mishra SK, Newton CR (2009) Diagnosis and management of the neurological complications of falciparum malaria. *Nat Rev Neurol* 5:189–198.
- White NJ, Turner GD, Medana IM, Dondorp AM, Day NP (2010) The murine cerebral malaria phenomenon. *Trends Parasitol* 26:11–15.
- Dorovini-Zis K, Prameya R, Bowman PD (1991) Culture and characterization of microvascular endothelial cells derived from human brain. *Lab Invest* 64:425–436.
- Xiao L, et al. (1996) *Plasmodium falciparum*: Involvement of additional receptors in the cytoadherence of infected erythrocytes to microvascular endothelial cells. *Exp Parasitol* 84:42–55.
- Wassmer SC, Cianciolo GJ, Combes V, Grau GE (2005) Inhibition of endothelial activation: A new way to treat cerebral malaria? *PLoS Med* 2:e245.
- Wassmer SC, Combes V, Candal FJ, Juhani-Vague I, Grau GE (2006) Platelets potentiate brain endothelial alterations induced by *Plasmodium falciparum*. *Infect Immun* 74:645–653.
- Claessens A, Rowe JA (2012) Selection of *Plasmodium falciparum* parasites for cytoadhesion to human brain endothelial cells. *J Vis Exp* 59:e3122.
- Tembo D, Montgomery J (2010) Var gene expression and human *Plasmodium* pathogenesis. *Future Microbiol* 5:801–815.
- Rowe JA, Claessens A, Corrigan RA, Arman M (2009) Adhesion of *Plasmodium falciparum*-infected erythrocytes to human cells: Molecular mechanisms and therapeutic implications. *Expert Rev Mol Med* 11:e16.
- Kraemer SM, Smith JD (2006) A family affair: var genes, PfEMP1 binding, and malaria disease. *Curr Opin Microbiol* 9:374–380.
- Smith JD, Subramanian G, Gamain B, Baruch DI, Miller LH (2000) Classification of adhesive domains in the *Plasmodium falciparum* erythrocyte membrane protein 1 family. *Mol Biochem Parasitol* 110:293–310.
- Robinson BA, Welch TL, Smith JD (2003) Widespread functional specialization of *Plasmodium falciparum* erythrocyte membrane protein 1 family members to bind CD36 analysed across a parasite genome. *Mol Microbiol* 47:1265–1278.
- Janes JH, et al. (2011) Investigating the host binding signature on the *Plasmodium falciparum* PfEMP1 protein family. *PLoS Pathog* 7:e1002032.
- Kirchgatter K, Portillo Hdela (2002) Association of severe noncerebral *Plasmodium falciparum* malaria in Brazil with expressed PfEMP1 DBL1 alpha sequences lacking cysteine residues. *Mol Med* 8:16–23.
- Jensen AT, et al. (2004) *Plasmodium falciparum* associated with severe childhood malaria preferentially expresses PfEMP1 encoded by group A var genes. *J Exp Med* 199:1179–1190.
- Kyriacou HM, et al. (2006) Differential var gene transcription in *Plasmodium falciparum* isolates from patients with cerebral malaria compared to hyperparasitaemia. *Mol Biochem Parasitol* 150:211–218.
- Warimwe GM, et al. (2009) *Plasmodium falciparum* var gene expression is modified by host immunity. *Proc Natl Acad Sci USA* 106:21801–21806.
- Rowe JA, Moulds JM, Newbold CI, Miller LH (1997) *P. falciparum* rosetting mediated by a parasite-variant erythrocyte membrane protein and complement-receptor 1. *Nature* 388:292–295.
- Vigan-Womas I, et al. (2008) An in vivo and in vitro model of *Plasmodium falciparum* rosetting and autoagglutination mediated by varO, a group A var gene encoding a frequent serotype. *Infect Immun* 76:5565–5580.
- Vigan-Womas I, et al. (2011) Allelic diversity of the *Plasmodium falciparum* erythrocyte membrane protein 1 entails variant-specific red cell surface epitopes. *PLoS ONE* 6:e16544.
- Ghumra A, et al. (2011) Immunisation with recombinant PfEMP1 domains elicits functional rosette-inhibiting and phagocytosis-inducing antibodies to *Plasmodium falciparum*. *PLoS ONE* 6:e16414.
- Ghumra A, et al. (2012) Induction of Strain-Transcending Antibodies Against Group A PfEMP1 Surface Antigens from Virulent Malaria Parasites. *PLoS Pathog* 8:e1002665.
- Claessens A, et al. (2011) Design of a variant surface antigen-supplemented microarray chip for whole transcriptome analysis of multiple *Plasmodium falciparum* cytoadherent strains, and identification of strain-transcendent rif and stevor genes. *Malar J* 10:180.
- Crabb BS, et al. (1997) Targeted gene disruption shows that knobs enable malaria-infected red cells to cytoadhere under physiological shear stress. *Cell* 89:287–296.
- Seydel KB, Milner DA, Jr., Kamiza SB, Molyneux ME, Taylor TE (2006) The distribution and intensity of parasite sequestration in comatose Malawian children. *J Infect Dis* 194:208–215.
- Biswas AK, et al. (2007) *Plasmodium falciparum* uses gC1qR/HABP1/p32 as a receptor to bind to vascular endothelium and for platelet-mediated clumping. *PLoS Pathog* 3:1271–1280.
- Andrews KT, Adams Y, Viebig NK, Lanzer M, Schwartz-Albiez R (2005) Adherence of *Plasmodium falciparum* infected erythrocytes to CHO-745 cells and inhibition of binding by protein A in the presence of human serum. *Int J Parasitol* 35:1127–1134.
- Berendt AR, et al. (1992) The binding site on ICAM-1 for *Plasmodium falciparum*-infected erythrocytes overlaps, but is distinct from, the LFA-1-binding site. *Cell* 68:71–81.
- Bozdech Z, et al. (2003) The transcriptome of the intraerythrocytic developmental cycle of *Plasmodium falciparum*. *PLoS Biol* 1:E5.
- Taylor HM, Kyes SA, Harris D, Kriek N, Newbold CI (2000) A study of var gene transcription in vitro using universal var gene primers. *Mol Biochem Parasitol* 105:13–23.
- Bull PC, et al. (2005) *Plasmodium falciparum* variant surface antigen expression patterns during malaria. *PLoS Pathog* 1:e26.
- Wang CW, Magistrado PA, Nielsen MA, Theander TG, Lavstsen T (2009) Preferential transcription of conserved rif genes in two phenotypically distinct *Plasmodium falciparum* parasite lines. *Int J Parasitol* 39:655–664.
- Kyes SA, Rowe JA, Kriek N, Newbold CI (1999) Rifins: A second family of clonally variant proteins expressed on the surface of red cells infected with *Plasmodium falciparum*. *Proc Natl Acad Sci USA* 96:9333–9338.
- Llinás M, Bozdech Z, Wong ED, Adai AT, DeRisi JL (2006) Comparative whole genome transcriptome analysis of three *Plasmodium falciparum* strains. *Nucleic Acids Res* 34:1166–1173.
- Sargeant TJ, et al. (2006) Lineage-specific expansion of proteins exported to erythrocytes in malaria parasites. *Genome Biol* 7:R12.
- Pasloske BL, et al. (1993) Cloning and characterization of a *Plasmodium falciparum* gene encoding a novel high-molecular weight host membrane-associated protein, PfEMP3. *Mol Biochem Parasitol* 59:59–72.
- Brown GV, et al. (1985) Localization of the ring-infected erythrocyte surface antigen (RESA) of *Plasmodium falciparum* in merozoites and ring-infected erythrocytes. *J Exp Med* 162:774–779.
- Spycher C, et al. (2003) MAHRP-1, a novel *Plasmodium falciparum* histidine-rich protein, binds ferriprotoporphyrin IX and localizes to the Maurer's clefts. *J Biol Chem* 278:35373–35383.
- Rask TS, Hansen DA, Theander TG, Gorm Pedersen A, Lavstsen T (2010) *Plasmodium falciparum* erythrocyte membrane protein 1 diversity in seven genomes—divide and conquer. *PLoS Comput Biol* 6:e1000933.
- Cham GK, et al. (2008) A semi-automated multiplex high-throughput assay for measuring IgG antibodies against *Plasmodium falciparum* erythrocyte membrane protein 1 (PfEMP1) domains in small volumes of plasma. *Malar J* 7:108.
- Avril M, et al. (2012) A restricted subset of var genes mediates adherence of *Plasmodium falciparum*-infected erythrocytes to brain endothelial cells. *Proc Natl Acad Sci USA* 109:E1782–E1790.
- Lavstsen T, et al. (2012) *Plasmodium falciparum* erythrocyte membrane protein 1 domain cassettes 8 and 13 are associated with severe malaria in children. *Proc Natl Acad Sci USA* 109:E1791–E1800.
- Tham WH, Payne PD, Brown GV, Rogerson SJ (2007) Identification of basic transcriptional elements required for rif gene transcription. *Int J Parasitol* 37:605–615.
- Spycher C, et al. (2008) The Maurer's cleft protein MAHRP1 is essential for trafficking of PfEMP1 to the surface of *Plasmodium falciparum*-infected erythrocytes. *Mol Microbiol* 68:1300–1314.

47. Mok BW, et al. (2007) Comparative transcriptomal analysis of isogenic *Plasmodium falciparum* clones of distinct antigenic and adhesive phenotypes. *Mol Biochem Parasitol* 151:184–192.
48. Daily JP, et al. (2005) In vivo transcriptome of *Plasmodium falciparum* reveals overexpression of transcripts that encode surface proteins. *J Infect Dis* 191:1196–1203.
49. Eksi S, et al. (2005) Identification of a subtelomeric gene family expressed during the asexual-sexual stage transition in *Plasmodium falciparum*. *Mol Biochem Parasitol* 143: 90–99.
50. Mayer C, Slater L, Erat MC, Konrat R, Vakonakis I (2012) Structural analysis of the *Plasmodium falciparum* erythrocyte membrane protein 1 (PfEMP1) intracellular domain reveals a conserved interaction epitope. *J Biol Chem* 287:7182–7189.
51. Normark J, et al. (2007) PfEMP1-DBL1alpha amino acid motifs in severe disease states of *Plasmodium falciparum* malaria. *Proc Natl Acad Sci USA* 104:15835–15840.
52. Rowe JA, Shafi J, Kai OK, Marsh K, Raza A (2002) Nonimmune IgM, but not IgG binds to the surface of *Plasmodium falciparum*-infected erythrocytes and correlates with rosetting and severe malaria. *Am J Trop Med Hyg* 66:692–699.
53. Ochola LB, et al. (2011) Specific receptor usage in *Plasmodium falciparum* cytoadherence is associated with disease outcome. *PLoS ONE* 6:e14741.
54. Newbold C, et al. (1997) Receptor-specific adhesion and clinical disease in *Plasmodium falciparum*. *Am J Trop Med Hyg* 57:389–398.
55. Rogerson SJ, et al. (1999) Cytoadherence characteristics of *Plasmodium falciparum*-infected erythrocytes from Malawian children with severe and uncomplicated malaria. *Am J Trop Med Hyg* 61:467–472.
56. Heddini A, et al. (2001) Fresh isolates from children with severe *Plasmodium falciparum* malaria bind to multiple receptors. *Infect Immun* 69:5849–5856.
57. Fernandez-Reyes D, et al. (1997) A high frequency African coding polymorphism in the N-terminal domain of ICAM-1 predisposing to cerebral malaria in Kenya. *Hum Mol Genet* 6:1357–1360.
58. Craig A, et al. (2000) A functional analysis of a natural variant of intercellular adhesion molecule-1 (ICAM-1 Kilifi). *Hum Mol Genet* 9:525–530.
59. Fry AE, et al. (2008) Variation in the ICAM1 gene is not associated with severe malaria phenotypes. *Genes Immun* 9:462–469.
60. Howell DP, et al. (2008) Mapping a common interaction site used by *Plasmodium falciparum* Duffy binding-like domains to bind diverse host receptors. *Mol Microbiol* 67:78–87.
61. Corrigan RA, Rowe JA (2010) Strain variation in early innate cytokine induction by *Plasmodium falciparum*. *Parasite Immunol* 32:512–527.
62. Kraemer SM, et al. (2007) Patterns of gene recombination shape var gene repertoires in *Plasmodium falciparum*: Comparisons of geographically diverse isolates. *BMC Genomics* 8:45.